Plant Summary
Plant Information
TCMBank_ID: | TCMBANKHE008555 |
ID: | TCMBANKHE008555 |
植物拉丁名: |
|
功能与主治: | To lower cholesterol, enrich yin and nourish blood, moisten intestines and free stool, interrupt malaria, dispel wind, resolve toxin./Backache, neurasthenia, hyperlipemia, neurosis, insomnia, dizziness due to anemia, palpitation, limp aching lumbus and knees due to liver kidney yin vacuity, premature graying in beard and hair, tinnitus, emission, intestinal dry and constipation, enduring malaria, wind papule itching, sore and welling abscess, scrofula, hemorrhoids. |
药用植物名: | 何首乌 |
药用部位: | tuberoid |
药味: | Cold; Minor Warm; Sour; Bitter |
经络: | Liver; Kidney |
临床特征: | 1. The prepared sample can promote lymphocyte transformation.2. Reducing serum cholesterol, and relieving atherosclerosis.3. The crude sample is a purgative. |
治疗类型: | 补虚 |
TCM_ID_id: | 6281 |
TCMSP_id: | 325 |
植物对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN000819 | Rhein diglucoside | 9,10-dioxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyanthracene-2-carboxylic acid; AC1NT01N; rhein diglucoside | 608.55 | C1=CC2=C(C(=C1)OC3C(C(C(C(O3)CO)O)O)O)C(=O)C4=C(C=C(C=C4C2=O)C(=O)O)OC5C(C(C(C(O5)CO)O)O)O | |
| TCMBANKIN001519 | 1,3-dihydroxy-2-methoxy xanthone | C14H10O5 | COC1=C(C=C2C(=C1O)C(=O)C3=CC=CC=C3O2)O | ||
| TCMBANKIN001919 | stilbene glycoside | 0 | |||
| TCMBANKIN002616 | 4,4'-dihydroxy diphenyl methane | 4,4'-dihydroxydiphenyl methane; 4,4'-dihydroxydiphenylmethane | C13H12O2 | 200.23 | C1=CC(=CC=C1CC2=CC=C(C=C2)O)O |
| TCMBANKIN004134 | emodin-8-o-beta-d-glucoside | C21H20O10 | 0 | CC1=CC(=C2C(=C1)C(=O)C3=CC(=CC(=C3C2=O)O)OC4C(C(C(C(O4)CO)O)O)O)O | |
| TCMBANKIN004638 | polygalacic acid | SMR001215693; CHEMBL1722733; polygalacicacid; NCGC00247514-01; Polygalacic acid; MLS000575020; HMS2268O05 | C30H48O6 | 504.7 g/mol | CC1(CCC2(C(C1)C3=CCC4C(C3(CC2O)C)(CCC5C4(CC(C(C5(C)CO)O)O)C)C)C(=O)O)C |
| TCMBANKIN004739 | Polygonumoside C | ||||
| TCMBANKIN004991 | 1-o-mthylemodin | 0 | |||
| TCMBANKIN005634 | chrysarobin | CTK6B5714; CHEMBL1939839; NSC-6152; 6-methylanthracene-1,2,8-triol; NSC-112922; ZINC1693303; NSC6152; NCI60_004975; NSC112922; AC1L5AD0 | C15H12O3 | 240.25 g/mol | CC1=CC2=C(C=C3C(=C2)C=CC(=C3O)O)C(=C1)O |
| TCMBANKIN007972 | 6-Dodecanone | AI3-07073; 6064-27-3; dodecan-6-one | C12H24O | 184.32 | CCCCCCC(=O)CCCCC |
| TCMBANKIN009785 | polygonumoside A | C27H24O13 | 556.5 g/mol | C1C(OC2=C3C(=CC(=C21)OC4C(C(C(C(O4)CO)O)O)O)OC(=O)C5=CC(=C(C(=C53)O)O)O)C6=CC=C(C=C6)O | |
| TCMBANKIN010980 | n-transferuloyl-3-methyldopamine | 0 | |||
| TCMBANKIN011773 | Mu Ping aristolochic amide | ||||
| TCMBANKIN021351 | procyanidin b-13'-o-gallate | procyanidin b1-3'-o-gallate | C37H30O16 | 730.6 g/mol | C1C(C(OC2=C1C(=CC(=C2C3C(C(OC4=CC(=CC(=C34)O)O)C5=CC(=C(C=C5)O)O)O)O)O)C6=CC(=C(C=C6)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O |
| TCMBANKIN022553 | Alfalfa prime-7-O-β-D- glucopyranoside | ||||
| TCMBANKIN023440 | 3,4,3',5'-Tetrahydroxystilbene-3-glucoside | MolPort-039-339-045; 94356-26-0; AKOS032949074; ZINC26972732; Piceatannol 3-glycoside; 3,4,3',5'-tetrahydroxystilbene-3-glucoside; CHEMBL109802; Piceatannol 3'-O-glucoside | C20H22O9 | 406.38 | C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)OC3C(C(C(C(O3)CO)O)O)O)O |
| TCMBANKIN024113 | tetrahydroxytaxadiene | C20H32O4 | CC1=C2C(C(C3(CCC(C(=C)C3CC(C2(C)C)CC1O)O)C)O)O | ||
| TCMBANKIN024835 | acid anthrone | C20H20O6 | 0 | CCCCCC(=O)C1=C(C=C2CC3=CC(=CC(=C3C(=O)C2=C1O)O)O)O | |
| TCMBANKIN025498 | Emodinanthrone | 1,6,8-trihydroxy-3-methyl-10-hydroanthracen-9-one; 6-Methyl-1,3,8,9-anthracenetetrol; SCHEMBL6046328; Frangula emodin anthrone; 2,4,5-trihydroxy-7-methylanthracen-10(9H)-one; 491-60-1; UNII-77C500W1A2; emodin anthrone; AC1L3UZ6; Frangulaemodinanthrone; Frangulaemodinanthranol; AN-15164; AIDS-002046; ZINC6070245; 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one; Emodinanthranol; Protophyscihydrone; AKOS025401350; 1,3,8-Trihydroxy-6-methyl-9(10H)-Anthracenone; BDBM50060878; Emodinol; 1,3,8-trihydroxy-6-methyl-10H-anthracen-9-one; 1,3,8-Trihydroxy-6-methylanthrone; 9(10H)-Anthracenone, 1,3,8-trihydroxy-6-methyl-; CHEMBL122192; Emodin anthrone; AC-1208; 491E601; D00BSX; emodin anthrone ; DTXSID80197684; LAJSXCAVRQXZIO-UHFFFAOYSA-N; BC228045; AIDS002046; 77C500W1A2 | C15H12O4 | 256.25 | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2)C=C(C=C3O)O |
| TCMBANKIN025693 | 6-methoxy-2-methyl-1, 2,3, 4-tetrahydrO-β-carboline | ||||
| TCMBANKIN027562 | polygoacetophenoside | C14H18O10 | 346.29 | CC(=O)C1=C(C(=C(C=C1O)O)OC2C(C(C(C(O2)CO)O)O)O)O | |
| TCMBANKIN029967 | 2,3,5,4-tetrahydroxy-stilbene-2-O-β-D-6 ''-(α-D- glucose pyranose-yl)- glucopyranoside), Polygonum propionic prime | ||||
| TCMBANKIN031942 | questinol | 1,6-Dihydroxy-3-hydroxymethyl-8-methoxyanthraquinone; 35688-09-6; omega-Hydroxymethylemodin; DTXSID50189192; Questinol_120239; Questinol; 9,10-Anthracenedione, 1,6-dihydroxy-3-(hydroxymethyl)-8-methoxy-; 1,6-Dihydroxy-3-(hydroxymethyl)-8-methoxy-9,10-anthracenedione; SCHEMBL16226232; 1,6-dihydroxy-3-(hydroxymethyl)-8-methoxy-9,10-dihydroanthracene-9,10-dione; CHEBI:81349; C17811; AC1L3VJY; 1,6-dihydroxy-3-(hydroxymethyl)-8-methoxyanthracene-9,10-dione; 1-Hydroxy-3-(hydroxymethyl)-6-hydroxy-8-methoxy-9,10-anthraquinone; 1,6-dihydroxy-3-(hydroxymethyl)-8-methoxy-anthracene-9,10-dione; 1,6-dihydroxy-8-methoxy-3-methylol-9,10-anthraquinone | C16H12O6 | 300.26 g/mol | COC1=CC(=CC2=C1C(=O)C3=C(C2=O)C=C(C=C3O)CO)O |
| TCMBANKIN032488 | physcion-8-o-beta-d-glucoside | C22H22O10 | 446.4 g/mol | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3OC4C(C(C(C(O4)CO)O)O)O)OC | |
| TCMBANKIN032605 | B Su Polygonum | ||||
| TCMBANKIN033528 | HE SHOU WU | ||||
| TCMBANKIN035682 | emodin-1 | C15H9O5- | CC1=CC(=C2C(=C1)C(=O)C3=CC(=CC(=C3C2=O)[O-])O)O | ||
| TCMBANKIN036792 | rhein | 4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid; 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; 4,5-dihydroxy-7-methyl-9,10-dioxo-anthracene-2-carboxylic acid; SBB001152; C10401; AIDS001379; CCRIS 5129; Rhein; MLS000069639; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo- (8CI); 4,5-DiOH-anthraquinone-2-COOH; 2-Anthroic acid, 9,10-dihydro-4,5-dihydroxy-9,10-dioxo-; ACon1_000217; 2-Anthracenecarboxylic acid, 9,10-dihydro-4,5-dihydroxy-7-methyl-9,10-dioxo-; 4,5-dihydroxy-anthraquinone-2-carboxylic acid; SMR000058210; 4,5-Dihydroxy-2-anthraquinonecarboxylic acid; 1,8-DIHYDROXY-3-CARBOXYL ANTHRAQUINONE; 4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; MEGxp0_001866; LMPK02000044; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracene carboxylic acid; AC1MHQNE; Rhubarb yellow; 4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; 1,8-Dihydroxyanthraquinone-3-carboxylic acid; 275611_ALDRICH; NSC38629; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-anthracenecarboxylic acid; 4-10-00-04088 (Beilstein Handbook Reference); EINECS 207-521-4; Chrysazin-3-carboxylic acid; NSC 38629; Rhein (1,8-dihydroxy-3-carboxyl anthraquinone); 478-43-3; Monorhein; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxoanthracene-2-carboxylic acid; Cassic acid; 4,5-dihydroxy-9,10-dioxo-anthracene-2-carboxylic acid; Rheic acid; AIDS-001379; 4,5-Dihydroxyanthraquinone-2-carboxylic acid; SCHEMBL18601968; R7269_SIGMA; NCGC00023342-03; 4,5-dihydroxy-7-methyl-9,10-dioxoanthracene-2-carboxylic acid; BRN 2222155; 4,5-dihydroxy-9,10-diketo-anthracene-2-carboxylic acid | C15H10O6 | 286.236 | c1([H])c(O[H])c(C(=O)[C@]([H])(C(O[H])=C([H])C(C(O[H])=O)=C2[H])[C@@]2([H])C3=O)c3c([H])c1[H] |
| TCMBANKIN036824 | 2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside | 2,3,5,4'-tetrahydroxystilbene-2-o-beta-d-glucoside | 406.4 g/mol | ||
| TCMBANKIN037382 | Aloeemodin | AC1Q6JR7; SMP2_000291; Aloe-emodol; 1,8-Dihydroxy-3-(hydroxymethyl)anthra-9,10-quinone; DSSTox_RID_78855; AS-11638; NCGC00163510-02; HY-N0189; CCG-208456; Diacerein impurity B, European Pharmacopoeia (EP) Reference Standard; AJ-48016; DTXSID2030695; BC216172; TL8003252; 3-(Hydroxymethyl)chrysazin; MLS000697563; BBL027838; 1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione; AK160272; 481-72-1; aloe emodine; MCULE-6965338444; RP29614; 1, 8-dihydroxy-3-hydroxymethylanthraquinone; BB_NC-2562; NCGC00255349-01; C10294; SR-01000765772; BG00617009; 9, 1,8-dihydroxy-3-(hydroxymethyl)-; ST24045939; DSSTox_CID_10695; Tox21_302400; NCGC00163510-03; Anthraquinone,8-dihydroxy-3-(hydroxymethyl)-; 1,8-Dihydroxy-3-(hydroxymethyl)anthra-9,10-quinone #; 1,8-Dihydroxy-3-hydroxymethyl-9,10-anthracenedione, 9CI; Aloeemodin; s2259; CS-3709; TR-031339; 1,8-Dihydroxy-3-hydroxymethylanthraquinone; 4-08-00-03578 (Beilstein Handbook Reference); AIDS-048396; InChI=1/C15H10O5/c16-6-7-4-9-13(11(18)5-7)15(20)12-8(14(9)19)2-1-3-10(12)17/h1-5,16-18H,6H; 1,8-dihydroxy-3-(hydroxymethyl)-9,10-anthrachinon; CAS-481-72-1; EINECS 207-571-7; UNII-C8IYT9CR7C; LMPK13040002; AC-020; NSC-38628; 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2-hydroxymethyl-anthracene; 1,8-dihydroxy-3-methylol-9,10-anthraquinone; CCRIS 3526; AC1L1UPK; BG01563188; LS-2202; 1,8-dihydroxy-3-hydroxymethyl-anthraquinone; Aloe emodin; AX8006287; SR-01000765772-3; Q-100526; SC-46578; 3-Hydroxymethylchrysazin; Rhabarberone; AIDS048396; NSC 38628; BRN 2059062; C8IYT9CR7C; N1851; 1,8-Dihydroxy-3-(hydroxymethyl)-9,10-anthracenedione; AB0010470; Aloe-emodin, >=95% (HPLC); ZINC4098644; aloe emodin; HMS3655N16; D09BUG; CHEMBL40275; 1,8-Dihydroxy-3-(hydroxymethyl)-anthracene-9,10-dione (Aloe-Emodin); NCGC00163510-01; MLS006011799; 1,8-Dihydroxy-3-(hydroxymethyl)anthraquinone; AN-16215; NCI60_003685; Aloeemodin:9,10-Anthracenedione,1,8-dihydroxy-3-(hydroxymethyl)-,; cid_10207; 3-Hydroxymethylchrysazine; Aloe-emodin; SMR000470920; aloeemod-in; MFCD00017373; LMPK02000031; STL146380; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)-; MolPort-003-931-716; FT-0622062; aloe-emodin; API0001418; 1,8-dihydroxy-3-(hydroxymethyl)anthra-9,10-quinone; Rottlerin?; ANTHRAQUINONE, 1,8-DIHYDROXY-3-HYDROXYMETHYL-; A7687_SIGMA; I14-1413; 9,10-Anthracenedione, 1,8-dihydroxy-3-(hydroxymethyl)- (9CI); CA-417; BDBM50085551; Aloe-emodine; YDQWDHRMZQUTBA-UHFFFAOYSA-N; NSC38628; Aloe-emodin, analytical standard; AKOS005720864; aloe-emodin ; SCHEMBL309756; 481A721; EMODINE; Anthraquinone, 1,8-dihydroxy-3-(hydroxymethyl)-; CHEBI:2607; DSSTox_GSID_30695; CA0128 | 270.24 | ||
| TCMBANKIN039813 | 1,3-Dihydroxy-6,7-dimethylxanthone-1-O-beta-D-glucoside | 1,3-dihydroxy-6,7-dimethylxanthone-1-o-β-d-glucoside | C21H22O9 | 418.394 | c1([H])c(O[H])c([H])c(Oc(c([H])c(C([H])([H])[H])c(C([H])([H])[H])c2[H])c2C3=O)c3c1O[C@@]4([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O4 |
| TCMBANKIN040831 | tricin | NSC294579; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4-chromenone; AIDS-120640; 3',5'-O-dimethyltricetin; CHEBI:60016; 3',5'-di-O-methyltricetin(1-); 5,7,4-trihydroxy-3, 5-dimethoxyflavone; 3',5'-di-O-methyltricetin; 520-32-1; Tricetin 3',5'-di-methyl ether; Tricin; C10193; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4H-1-benzopyran-4-one; AIDS120640; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromen-4-one; NSC 294579; 4',5,7-trihydroxy-3',5'-dimethoxyflavone; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromone; 5-hydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4-oxo-4H-chromen-7-olate | C17H14O7 | 330.289 | c1(O[H])c(OC([H])([H])[H])c([H])c(C2=C([H])C(=O)c3c(c([H])c(O[H])c([H])c3O[H])O2)c([H])c1OC([H])([H])[H] |
| TCMBANKIN041527 | Chrysophanol-8-O-beta-D-(6'-O-galloyl)-glucopyranoside | [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-1-anthryl)oxy]tetrahydropyran-2-yl]methyl 3,4,5-trihydroxybenzoate; 3,4,5-trihydroxybenzoic acid [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-6-methyl-9,10-dioxo-1-anthryl)oxy]-2-tetrahydropyranyl]methyl ester; [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(8-hydroxy-6-methyl-9,10-dioxo-anthracen-1-yl)oxy-oxan-2-yl]methyl 3,4,5-trihydroxybenzoate; Chrysophanol 8-(6-O-galloyl-beta-D-glucopyranoside); [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(8-hydroxy-6-methyl-9,10-dioxoanthracen-1-yl)oxyoxan-2-yl]methyl 3,4,5-trihydroxybenzoate; 3,4,5-trihydroxybenzoic acid [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[(8-hydroxy-9,10-diketo-6-methyl-1-anthryl)oxy]tetrahydropyran-2-yl]methyl ester; chrysophanol-8-o-beta-d-(6'-o-galloyl)-glucopyranoside; AC1NSTKE; CHEMBL109609 | C28H24O13 | 568.5 g/mol | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3OC4C(C(C(C(O4)COC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)O |
| TCMBANKIN042817 | 2,3,5,4'-tetrahydroxystilbene-2-o-(6''-o-acetyl)-beta-d-glucopyranoside | 2,3,5,4'-tetrahydroxystilbene-2-o-(6''-o-acetyl)-β-d-glucopyranoside | 448.42 | CC(=O)OCC1C(C(C(C(O1)OC2=C(C=C(C=C2C=CC3=CC=C(C=C3)O)O)O)O)O)O | |
| TCMBANKIN042828 | 2,3,5,4'-tetrahydroxystilbene-2-o-(6''-o-alpha-d-glucopyranosyl)-beta-d-glucopyranoside | 2,3,5,4'-tetrahydroxystilbene-2-o-(6''-o-α-d-glucopyranosyl)-β-d-glucopyranoside | C26H32O14 | C1=CC(=CC=C1C=CC2=CC(=CC(=C2OC3C(C(C(C(O3)COC4C(C(C(C(O4)CO)O)O)O)O)O)O)O)O)O | |
| TCMBANKIN044012 | Quercetin-5,3-di-D-galactoside | quercetin-5,3-di-d-galactoside | 626.57 | ||
| TCMBANKIN045236 | fetidine | Fetidine; SCHEMBL2989372; SureCN2989372; C09441; CHEBI:5049; (6aS)-9-[6-[[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2,3-dimethoxy-phenoxy]-2,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-1-ol; DTXSID10331776; 7072-86-8; AC1L9CGQ | C40H46N2O8 | 682.8 g/mol | CN1CCC2=CC(=C(C3=C2C1CC4=CC(=C(C=C43)OC)OC5=C(C=CC(=C5OC)OC)CC6C7=CC(=C(C=C7CCN6C)OC)OC)O)OC |
| TCMBANKIN045518 | questin | questin-2-olate; 1,6-dihydroxy-8-methoxy-3-methylanthracene-9,10-dione; 3774-64-9; 1,6-dihydroxy-8-methoxy-3-methyl-9,10-anthraquinone; emodin-8-methyl ether; 5-hydroxy-4-methoxy-7-methyl-9,10-dioxo-9,10-dihydroanthracen-2-olate; 9,10-Anthracenedione, 1,6-dihydroxy-8-methoxy-3-methyl-; CHEBI:57676; 1,6-dihydroxy-3-methyl-8-(methyloxy)anthracene-9,10-dione; 3,8-dihydroxy-1-methoxy-6-methylanthracene-9,10-dione; 1,6-dihydroxy-8-methoxy-3-methyl-anthracene-9,10-dione; CHEBI:16200; C01448; Questin | C16H12O5 | 284.263 | c1([H])c(O[H])c(C(=O)c(c(OC([H])([H])[H])c([H])c(O[H])c2[H])c2C3=O)c3c([H])c1C([H])([H])[H] |
| TCMBANKIN058060 | gallic acid | Spectrum4_001544; NSC-755825; 4CN-0954; KBio2_000822; NCGC00260064-01; KBio3_001168; CHEBI:30778; GTPL5549; D0Y3TZ; NCGC00091125-01; 632XD903SP; ARONIS23903; Spectrum5_000108; Jsp002851; T7419; Gallic acid, puriss., 98.0%; I14-9302; NCGC00091125-07; ZINC1504; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); KBioGR_002008; AK-65266; pyrogallol-5-carboxylate; BRD-K77345217-001-01-9; Gallicum acidum; LNTHITQWFMADLM-UHFFFAOYSA-N; KBio2_003390; EBD679760; NCGC00091125-04; AJ-08037; Gallic acid; ZB000350; BG01502846; A808977; (?)-Gallic acid; WLN: QVR CQ DQ EQ; N1830; AC1NEVA5; SBB008781; 149-91-7; GALLIC ACID ANHYDROUS; Gallic acid [NF]; KS-00000IWM; CS-8191; LS-870; C01424; KS-00004784; CHEBI:16918; SPECTRUM210369; c0006; UNII-632XD903SP; ACMC-20aku5; CTK0H5618; BIDD:ER0374; AC1Q732X; NCGC00091125-02; F1908-0156; Oprea1_087792; CG0029; DSSTox_RID_75711; Kyselina 3,4,5-trihydroxybenzoova; 3-10-00-02070 (Beilstein Handbook Reference); RP23206; NSC36997; Gallic acid, certified reference material, TraceCERT(R); AI3-16412; CCG-38670; STK298718; Tox21_202515; bmse000389; AN-15162; AB00052697_03; SR-05000001537-2; NSC-36997; 1886-EP2374526A1; 5-Carboxybenzene-1,2,3-triol; KBio2_005958; SR-05000001537-3; NCGC00091125-05; KBio1_001347; Kyselina gallova [Czech]; KSC175M1R; KBioSS_000822; HMS2091A07; gallate; CPD-183; Spectrum3_000254; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; gallic acid ; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; GDE; SBI-0052184.P002; EINECS 205-749-9; CAS-149-91-7; Kyselina gallova; J3.617.291F; Benzoic acid, 3,4,5-trihydroxy-; BG00601456; DivK1c_006403; Benzoic acid,4,5-trihydroxy-; gallic acid for microelectronic industrial; BRN 2050274; Gallic acid tech.; NCGC00091125-03; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid, 97.5-102.5% (titration); gallicacid; 3,4,5-Trihydroxybenzoic acid, anhydrous; NSC674319; TR-020762; 3,4,5-tris(oxidanyl)benzoate; MCULE-1552954312; Gallic acid polymer; Pharmakon1600-00210369; BSPBio_001668; Tox21_111089; HMS1923K07; CCRIS 5523; BDBM50085536; NSC-674319; ST2404570; BB_SC-2795; AC-1206; 3,4,5-trihydroxy-Benzoic acid; Gallic Acid Hydrate; AC1L1934; RTR-020762; GALOP; Q-201146; SR-05000001537-1; DSSTox_CID_650; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; 3,4,5-Trihydroxybenzoic acid ion; GALLICACID; s4603; CHEMBL288114; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; NSC755825; G0011; AB1002218; Gallic Acid, F; MolPort-000-881-260; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; PS-8710; SC-46383; FT-0626592; BBL009937; MFCD00002510; SpecPlus_000307; 3,4,5-trihydroxy-Benzoate; SCHEMBL15012; DSSTox_GSID_20650; ST083487; SR-05000001537; 3,5-Trihydroxybenzoic acid; 3,4,5-Trihydroxybenzoate, X; Tox21_111089_1; Gallic acid (Monohydrate or Anhydrous) (3,4,5-Trih; 3,4,5-Trihydroxybenzoic acid;; Z966690556; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; BC200279; Spectrum2_000399; HY-N0523; HSDB 2117; AC1Q732Y; DTXSID0020650; 5-Trihydroxybenzoic acid; AKOS000119625; NSC 20103; Gallic acid, tech; 138-57-8; NSC-20103; AIDS-001349; gallate; CPD-183; Spectrum3_000254; KBio2_000822; Gallic acid monohydrate; AIDS-059239; KBio3_001168; Gallic acid, tech.; NSC20103; 3,4,5-Trihydroxybenzoic acid; InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; C01424; CHEBI:30778; EINECS 205-749-9; CHEBI:16918; NCGC00091125-01; c0006; J3.617.291F; SPECTRUM210369; Benzoic acid, 3,4,5-trihydroxy-; DivK1c_006403; NSC 674319; SPBio_000617; LNTHITQWFMADLM-UHFFFAOYSA-M; Spectrum_000342; Spectrum5_000108; NCGC00091125-02; BRN 2050274; Oprea1_087792; NCGC00091125-03; 3-10-00-02070 (Beilstein Handbook Reference); SpecPlus_000307; Kyselina 3,4,5-trihydroxybenzoova [Czech]; KBioGR_002008; AI3-16412; NSC674319; pyrogallol-5-carboxylate; 3,4,5-tris(oxidanyl)benzoate; AIDS001349; KBio2_003390; Gallic acid polymer; 1886-EP2374526A1; ZB000350; Gallic acid; BSPBio_001668; KBio2_005958; AIDS059239; CCRIS 5523; 3,4,5-Trihydroxybenzoate; SDCCGMLS-0066503.P001; Pyrogallol-5-carboxylic acid; A808977; 27645_RIEDEL; KBio1_001347; 398225_SIAL; Kyselina gallova [Czech]; WLN: QVR CQ DQ EQ; Spectrum2_000399; HSDB 2117; G7384_SIGMA; KBioSS_000822; GALOP; AC1NEVA5; SBB008781; 3,4,5-Trihydroxybenzoic acid monohydrate, ACS, 98.0% min. 100g; NSC 20103; 3,4,5-Trihydroxybenzoic acid ion; 149-91-7; 3,4,5-trihydroxybenzoic acid; Galllic acid | C7H6O5 | 170.12 | C1=C(C=C(C(=C1O)O)O)C(=O)O |
| TCMBANKIN058087 | w- hydroxy emodin | Citreorosein | C15H10O6 | 286.24 g/mol | C1=C(C=C(C2=C1C(=O)C3=C(C2=O)C(=CC(=C3)O)O)O)CO |
| TCMBANKIN058109 | Pyrogallic acid | PYG;1,2,3-Benzenetriol; Benzene, 1,2,3-trihydroxy-; 1,2,3-Trihydroxybenzene; BRN 0907431; Pyro; Piral; AIDS-002956; Fouramine Brown AP; ZINC00330141; P0381_SIGMA; 1,2,3-TRIHYDROXY-BENZENE; SMR000471842; 2,2',2"-[1,2,3-BENZENE-TRIYLTRIS(OXY)]TRIS[N,N,N-TRIETHYLETHANAMINIUM]; WLN: QR BQ CQ; 1,2,3-Trihydroxybenzen; 1,2,3-Trihydroxybenzen [Czech]; CI Oxidation Base 32; AIDS082397; Pyrogallol polymer; AIDS-082397; CCRIS 1940; Fourrine 85; C.I. 76515; fouramine base ap; InChI=1/C6H6O3/c7-4-2-1-3-5(8)6(4)9/h1-3,7-9; AIDS002956; Pyrogallic acid; C.I. Oxidation Base 32; AI3-00709; C01108; 254002_SIAL; Pyrogallol solution; CI 76515; HSDB 794; 87-66-1; CHEBI:16164; 83135_FLUKA; GMN; MLS001066376; Pyrogallol; C.I. Oxidation Base 32; 16040_RIEDEL; PYROP; Fourrine PG; 4-06-00-07327 (Beilstein Handbook Reference); BENZENE-1,2,3-TRIOL; NCGC00091507-01; AB-131/40221933; NSC5035; EINECS 201-762-9; c0025; NSC 5035;pyrogallol;Gallic phenol | C6H6O3 | 126.11 g/mol | C1=CC(=C(C(=C1)O)O)O |
| TCMBANKIN058205 | trans-resveratrol | (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene | C14H12O3 | 228.24 g/mol | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
| TCMBANKIN058207 | 2,3,5,4'-tetrahydroxystilbene-2,3-o-β-d-digluco-side | 2,3,5,4'-tetrahydroxystilbene-2,3-o-beta-d-glucoside | C26H32O14 | C1=CC(=CC=C1C=CC2=CC(=CC(=C2OC3C(C(C(C(O3)CO)O)O)O)OC4C(C(C(C(O4)CO)O)O)O)O)O | |
| TCMBANKIN058416 | chrysazin | LTAN;danthron;9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-dihydroxyanthra-9,10-quinone; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; Istan; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; Dantron; NSC 38626; AIDS-001375; EU-0099935; Danivac; EINECS 204-173-5; 1,8-Dihydroxy-9,10-anthraquinone; 117-10-2; Dionone; Laxanorm; CCRIS 3529; Dioxyanthrachinonum; KBio2_007366; Dorbanex; AI3-38117; NCGC00091367-02; NSC646568; Altan; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; 1,8-Dihydroxyanthracene-9,10-dione; Laxanthreen; KBioSS_002230; MEGxp0_001693; NSC 646568; 1,8-Dihydroxyanthraquinone; C10312; component of Modane; Danthron [BAN]; D108103_ALDRICH; Laxipur; Duolax; CHEBI:3682; BSPBio_002259; ZINC03860369; ST5330603; AIDS001375; Dantrona [INN-Spanish]; Dorbane; KBio3_001479; Zwitsalax; NSC7210; SPECTRUM211468; Scatron D; SMR000059018; Spectrum5_000324; Chrysazine; NSC38626; Danthron; Spectrum3_000650; Pastomin; Dantrone [INN-French]; KBio1_000284; MLS000069608; 1,8-Dihydroxyanthrachinon; component of Doxidan; IDI1_000284; Laxipurin; Antrapurol; DivK1c_000284; Diaquone; Bancon; Neokutin S; Dantronum [INN-Latin]; NCIMech_000114; Spectrum2_000603; 343235-40-5; Istizin; 32073-07-7; component of Doxan; SPBio_000506; KBio2_004798; component of Dorbantyl; 1,8-Dihydroanthraquinone; NINDS_000284; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; Prugol;danthron; Chrysazine; Danthron; CAS-117-10-2; Z4XE6IBF3V; NCGC00091367-05; 9,10-Anthracenedione, 1,8-dihydroxy-; KBioGR_001944; ACon1_000135; 3nsq; Spectrum4_001682; NCI60_041443; 1,8-Dihydroxy-9,10-anthracenedione; 1,8-bis(oxidanyl)anthracene-9,10-dione; Danthron [USP]; 1,8-Dihydroxyanthrachinon [Czech]; KBio2_002230; Roydan; DSSTox_CID_328; Istan; BBL013161; InChI=1/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16; dihydroxyanthraquino ne; 1,8-Dihydroxyanthraquinone, Vetec(TM) reagent grade, 96%; Chrysazin; Spectrum_001750; Modane; Usaf nd-59; HMS2091A09; Dantron; NSC 38626; 9, 1,8-dihydroxy-; Dantron, INN; NSC755828; SBI-0051330.P003; EU-0099935; Dantron [INN]; CCG-35470; DB04816; Danivac; HMS3715F08; D0J0EL; ST50330603; NCGC00091367-06; UNII-Z4XE6IBF3V; EINECS 204-173-5; Dantron (Chrysazin; 8,9-DIHYDROXYANTHRACENE-1,10-DIONE; 1,8-Dihydroxy-9,10-anthraquinone; danthro-lax; HSDB 7764; Dionone; 117-10-2; Laxanorm; CCRIS 3529; NSC-646568; Criasazin; Dioxyanthrachinonum; KBio2_007366; RTR-003068; Dorbanex; ANW-17004; SBB057973; AI3-38117; NCGC00258539-01; dianthon; Danthron (1,8-Dihydroxyanthracene-9,10-dione); STK238373; HMS500O06; 8,9-dihydroxy-1,10-anthraquinone; NSC646568; ZX-AT013456; NCGC00091367-02; Altan; 1,8-dioxyanthraquinone; NCGC00091367-01; Anthraquinone, 1,8-dihydroxy-; Laxanthreen; 1,8-Dihydroxyanthracene-9,10-dione; SR-01000721864-2; AB1006759; I14-16739; KBioSS_002230; 1,8-Dihydroxyanthra-9,10-quinone #; MEGxp0_001693; KS-00000W95; NSC 646568; 1,8-Dihydroxyanthraquinone; MolPort-000-564-798; C10312; AC1L1EU5; component of Modane; Danthron [BAN]; Laxipur; Duolax; DTXSID9020328; Laxapur; LTAN; 1,8-Dihydroxy-9,10-anthracenedione, 9CI; MFCD00001211; DSSTox_GSID_20328; CHEBI:3682; ZINC3860369; Danthron, BAN; BRD-K10065684-001-03-3; BSPBio_002259; danthrone; OR61434; NCGC00091367-04; CS-4392; LS-587; BG01537787; ZX-AS004388; SR-01000721864; s4561; NSC-7210; Dantrona [INN-Spanish]; FT-0624445; Dorbane; 1,8-Dihydroxyanthraquinone, 96%; KBio3_001479; Zwitsalax; CHEMBL53418; CTK3J0719; Tox21_111122; ARONIS23892; KSC490O1T; NSC7210; SPECTRUM211468; Scatron D; ACMC-20mzuc; SMR000059018; 140861-59-2; Spectrum5_000324; Dantrona; BG00609013; D07107; BDBM11316; AB00051961_09; Chrysazine; NSC38626; Spectrum3_000650; Pastomin; Dantrone [INN-French]; Dorbanex (Salt/Mix); KBio1_000284; MLS000069608; BRD-K10065684-001-02-5; CHRYSAZIN, PRACT; Dantronum; NSC-755828; 1,8-Dihydroxyanthrachinon; 1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione; Tox21_200986; Anthraquinone-related compound; Pilules Vinchy N.F. (TN); component of Doxidan; IDI1_000284; D0563; DSSTox_RID_75516; QBPFLULOKWLNNW-UHFFFAOYSA-N; Anthraquinone,8-dihydroxy-; Laxipurin; MCULE-5800615690; 1,8-Dihydroxyanthracene-9,10-dione (Danthron); A803710; Antrapurol; DivK1c_000284; HS-1003; Diaquone; Bancon; CTK0F1106; HY-B0923; AN-43229; 1,8-dihydroxy-anthraquinone; Dorbantyl; 1,8-Dihydroxyanthra-9,10-quinone; Dorbantyl (Salt/Mix); Neokutin S; Dantronum [INN-Latin]; AK208660; NCIMech_000114; TR-003068; Pharmakon1600-00211468; Spectrum2_000603; 343235-40-5; NCGC00091367-07; SCHEMBL83688; Istizin; SPBio_000506; component of Doxan; NSC-38626; 1,8 Dihydroxy Anthraquinone; 32073-07-7; Dantron (INN); W-108572; KBio2_004798; NCGC00091367-03; component of Dorbantyl; 1,8-Dihydroanthraquinone; R229; Dantrone; NINDS_000284; AKOS001583216; WLN: L C666 BV IVJ DQ NQ; 1,4,5,8-Tetroxyantraquinone; BB_NC-0487; C14H8O4; Tox21_111122_1; RP28420; Prugol; Istizine; BBC/171; 1,10-Anthracenedione, 8,9-dihydroxy- | C14H8O4 | 240.21 g/mol | C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O |
| TCMBANKIN058520 | catechin c;epicatechin;alpha-catechin;(-)epicatechin | epi-Catechol; (3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; SCHEMBL13350313; Epicatechin; (.+-.)-Epicatechol; (+/-)-Epicatechin; AC1L5SMJ; L-Epicatechin; Epicatechol, (-)-; 17334-50-8; NSC-81162; 2H-1-Benzopyran-3,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)-; epicatechin ; NSC81162; (3R)-2-(3,4-DIHYDROXYPHENYL)-3,4-DIHYDRO-2H-1-BENZOPYRAN-3,5,7-TRIOL; 2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3alpha,5,7-triol; NSC-81161; NSC81161;EINECS 207-710-1; KBio2_003207; SpecPlus_000267; (+/-)-Epicatechin; SMP1_000115; AIDS-001347; NSC81161; STOCK1N-16439; (-)-epicatechin; KBioGR_001538; NSC 81161; .alpha. Catechin; BCBcMAP01_000224; KBio1_001307; 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R,3R)-; CCRIS 7097; 2H-1-Benzopyran-3,5,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)- (9CI); C09727; (- )-epicatechin; KBio2_005775; Spectrum3_000243; KBioSS_000639; NCGC00015215-01; (-)-Epicatechin; 2-(3,4-Dihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3alpha,5,7-triol; 17334-50-8; ZINC00119988; (2R,3R)-2-(3,4-dihydroxyphenyl)chroman-3,5,7-triol; SCHEMBL13350313; (-)- epicatechin; (3R)-2-(3,4-DIHYDROXYPHENYL)-3,4-DIHYDRO-2H-1-BENZOPYRAN-3,5,7-TRIOL; (.+-.)-Epicatechol; E4018_SIGMA; CHEBI:28466; NSC81162; Spectrum4_000949; 525952_ALDRICH; NSC-81162; DivK1c_006363; 2545-08-6; (-)-(2R:3R)-5,7,3',4'-Tetrahydroxyflavan-3-ol; (−)-Epicatechin; AC1L5SMJ; Lopac-C-1251; NCGC00016415-02; (2R,3R)-2-(3,4-Dihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol; (3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; Spectrum5_000929; l-Acacatechin; AIDS001347; E1753_SIGMA; 39263_FLUKA; (-)epicatechin ; Epicatechin; 2H-1-Benzopyran-3,7-triol, 2-(3,4-dihydroxyphenyl)-3,4-dihydro-, (2R-cis)-; Spectrum2_000675; 490-46-0; KBio3_001126; KBio2_000639; Prestwick_203; (−)-cis-3,3′,4′,5,7-Pentahydroxyflavane; NCGC00016415-01; (-)-epicatechin ; Epicatechin-(-); SDCCGMLS-0066927.P001; CAS-7295-85-4; (- )- epicatechin; 2-(3,4-Dihydroxyphenyl)-2,3,4-trihydro-3,5,7-trihydroxychromene; SPBio_000769; L-Epicatechin; epi-Catechol; Oprea1_209947; NSC-81161; (-) epicatechin; SPECTRUM210206; BSPBio_001626; (2R,3R)-(-)-Epicatechin; Spectrum_000159; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; epi-Catechin; CAS-154-23-4; ACon1_001106; Epicatechol, (-)- | C15H14O6 | 290.27 | C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O |
| TCMBANKIN058939 | 2- acetyl furan;2- acetylfurfun;Acetylfuran;2-furyl methyl ketone;1-(2-furanyl)ethanone | 2-acetylfuran;BG01496319; InChI=1/C6H6O2/c1-5(7)6-3-2-4-8-6/h2-4H,1H; FT-0610977; Acetylfuran; CHEBI:59983; MolPort-000-871-221;Acetylfuran; NSC 49133; NSC49133; Ketone, 2-furyl methyl; A16254_ALDRICH; Furan, 2-acetyl-; 48200_FLUKA; FEMA No. 3163; MFCD00003242; | C6H6O2 | 110.11 g/mol | CC(=O)C1=CC=CO1 |
| TCMBANKIN059657 | tadeonal | C15H22O2 | 234.33 g/mol | CC1(CCCC2(C1CC=C(C2C=O)C=O)C)C | |
| TCMBANKIN059840 | 2,5-dimethylbenzaldehyde | C9H10O | 134.18 | CC1=CC(=C(C=C1)C)C=O | |
| TCMBANKIN059851 | physcion 1-o-beta-d-glucoside | C28H32O15 | 462.44 | CC1=CC(=C2C(=C1)C(=O)C3=CC(=CC(=C3C2=O)OC4C(C(C(C(O4)COC5C(C(C(C(O5)CO)O)O)O)O)O)O)OC)O | |
| TCMBANKIN059928 | emodin | C15H10O5 | 270.24 g/mol | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)O | |
| TCMBANKIN059929 | physcion | C16H12O5 | 284.26 g/mol | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3O)OC | |
| TCMBANKIN059931 | Physciondiglucoside | C28H32O15 | 608.54 | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=C(C=C3OC4C(C(C(C(O4)COC5C(C(C(C(O5)CO)O)O)O)O)O)O)OC | |
| TCMBANKIN059932 | chrysophanol | C15H10O4 | 254.24 | CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O | |
| TCMBANKIN060480 | Polygonumoside D | C50H80O23 | CC1CCC2(C(C3C(O2)CC4(C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)CO)O)OC9C(C(C(CO9)O)O)O)OC2C(C(C(C(O2)CO)O)O)O)O)O)C)C)O)C)OC1 | ||
| TCMBANKIN060691 | poriferast-5-en-3beta-ol;22,23-dihydrostigmasterol;gamma-sitosterol;clionasterol;beta-dihydrofucosterol | C29H50O | 414.71 g/mol | CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C | |
| TCMBANKIN060693 | Sitogluside | C35H60O6 | 576.85g/mol | CCC(CCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)OC5C(C(C(C(O5)CO)O)O)O)C)C)C(C)C | |
| TCMBANKIN060800 | propyl cyclopentane | C8H16 | 112.21 | CCCC1CCCC1 | |
| TCMBANKIN061216 | n-butyl-β-D-fructoufranoside | C10H20O6 | 236.26 g/mol | CCCCOC1(C(C(C(O1)CO)O)O)CO | |
| TCMBANKIN061574 | feruloyltyramine | n- cis-feruloyltyramine; NP-001984; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; NCGC00169550-01; N-Trans-Feruloyl Tyramine; Moupinamide, >=95% (LC/MS-ELSD); 66648-43-9; Alfrutamide; trans-N-Feruloyltyramine; (E)-3-(4-Hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxy-phenyl)-ethyl]-acrylamide; N-Feruloyltyramine; ZINC901461; MEGxp0_000693; Feruloyltyramine; Moupinamide; BRD-K98045316-001-01-0; MolPort-001-740-847; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-; MCULE-4768764740; n-trans-feruloyl-tyramine; W1092; (2E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; ACon1_001233; N-trans-Feruloyltyramine; (2,3)trans-N-(p-Hydroxyphenethyl)ferulamide; CHEMBL206555; 65646-26-6; n- trans-feruloyltyramine; N-Transferuloyl Tyramine; MFCD17214811; AKOS025287596; CHEBI:17818; C02717; AC1NQX6M; (E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; CHEBI:17818; 3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; AIDS113439; (2E)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; 3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (2,3)trans-N-(p-Hydroxyphenethyl)ferulamide; N-trans-Feruloyltyramine; C02717; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; 3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; N-Feruloyltyramine; 65646-26-6; (E)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; AIDS-113439; 66648-43-9; Feruloyltyramine; moupinamide; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-; ACon1_001233; (E)-3-(4-Hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxy-phenyl)-ethyl]-acrylamide; MEGxp0_000693; 2-Propenamide, 3-(4-hydroxy-3-methoxyphenyl)-N-(2-(4-hydroxyphenyl)ethyl)-, (2Z)-; 80510-09-4; (Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (Z)-3-(4-hydroxy-3-methoxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide; (Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl)ethyl]acrylamide; Moupinamide; n-trans-feruloyltyramine; N-E-feruloyl tyramine; n-cis-feruloyltyramine | C18H19NO4 | 313.3 g/mol | COC1=C(C=CC(=C1)C=CC(=O)NCCC2=CC=C(C=C2)O)O |
| TCMBANKIN061667 | 5,7,4'-trihydroxy-6-methoxyflavanone | 6-Methoxynaringenin;5,7,4'-trihydroxy-8-methoxyflavanone;AC1NT16C; 5,7,4/'-Trihydroxy-6-methoxyflavanone; AK104440; 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-6-METHOXY-2,3-DIHYDRO-1-BENZOPYRAN-4-ONE; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-6-methoxychroman-4-one; AKOS022184707; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-2,3-dihydrochromen-4-one; 5,7,4'-trihydroxy-6-methoxydihydroflavone; 6-Methoxynaringenin; 4CN-1869; 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-methoxy-3,4-dihydro-2H-1-benzopyran-4-one; ST24044117; W1586; 5,7,4'-Trihydroxy-6-methoxyflavanone; 94942-49-1; LMPK12140619 | C16H14O6 | 302.28 g/mol | COC1=C(C2=C(C=C1O)OC(CC2=O)C3=CC=C(C=C3)O)O |
| TCMBANKIN061753 | tricin | 5,7,4′-Trihydroxy-3′,5′-dimethoxyflavone; NSC294579; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4-chromenone; AIDS-120640; 3',5'-O-dimethyltricetin; CHEBI:60016; 3',5'-di-O-methyltricetin(1-); 5,7,4-trihydroxy-3, 5-dimethoxyflavone; 3',5'-di-O-methyltricetin; 520-32-1; Tricetin 3',5'-di-methyl ether; Tricin; C10193; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4H-1-benzopyran-4-one; AIDS120640; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromen-4-one; NSC 294579; 4',5,7-trihydroxy-3',5'-dimethoxyflavone; 5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromone; 5-hydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4-oxo-4H-chromen-7-olate | C17H14O7 | 330.29 | COC1=CC(=CC(=C1O)OC)C2=CC(=O)C3=C(C=C(C=C3O2)O)O |
植物对应的疾病
| 疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
|---|
植物对应的靶点
| 靶点ID | 基因名 | 基因别名 | 描述 | 染色体位置 | Map_Location | 基因类型 |
|---|
滇ICP备16009434号-1 |
Dai SX Lab